Lupin launches Potassium Chloride Oral Solution in US Markets

Lupin has launched Potassium Chloride Oral Solution USP, 20 mEq/15mL (10 per cent) and 40 mEq/15 mL (20 per cent) in the US markets. The drug is a generic equivalent of Genus Lifesciences’s Potassium Chloride Oral Solution. It is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods and/or diuretic dose reduction are insufficient.

The Potassium Chloride Oral Solution USP, 20 mEq/15mL (10 per cent) and 40 mEq/15 mL (20 per cent), had annual sales of approximately USD 184.95 million in the US.